Potential of a COX-2 inhibitor in lowering chemotherapy-induced neutropenia

作     者：Louis Wing-Cheong Chow Adrian Yun-San Yip Eleanor Yuen-Yuen Ong Chi-Kei Lam Masakazu Toi 

作者机构：Clinical Trials CentreLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong Organisation for Oncology and Translational Research Comprehensive Centre for Breast DiseasesUNI MED Medical Institute Department of SurgeryKyoto UniversityJapan 

出 版 物：《中华乳腺病杂志（电子版）》 (Chinese Journal of Breast Disease(Electronic Edition))

年 卷 期：2010年第4卷第5期

页      面：8-13页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：血疗法 乳腺癌 治疗 临床 

摘      要：Objective This study was initially designed to evaluate the effect of celecoxib on the regimen of 5-fluorouracil,epirubicin,and cyclophosphamide(FEC)combination,followed by docetaxel(T)in neoadjuvant *** unplanned preliminary review on safety was conducted after a halt of the study due to the concerned potential cardiovascular risk of using COX-2 *** We studied 23 consecutive cases of operable breast cancer having received four cycles of FEC(500 mg/m2,100 mg/m2,500 mg/m2)followed by four cycles of T(100 mg/m2)with concurrent celecoxib(400 mg twice daily)(group A)or same chemotherapy regimen but without concurrent celecoxib(group B).These combined chemotherapies were administered every 3 *** Chi-square test or Fisher s exact test were used to assess the difference in incidence of limiting hematological toxicites between *** 23 patients(group A:n=12;group B,n=11)received a total of 183 out of 184 planned treatment cycles;one(4%,1/23)of them omitted the fourth cycle of FEC owing to repeated incidences of febrile *** dose intensity(RDI)for FEC in group A(90%±11%)was higher than that in group B(80%±8%)while RDI for T was similar between group A(93%±8%)and group B(96%±9%).Of the first 91 treatment cycles of FEC,limiting hematological toxicity,severe neutropenia including febrile neutropenia,was significantly different between group A and B [(10.4%,5/48)vs.(32.6%,14/43),P=0.009].Other toxicities commonly observed in chemotherapy receiving patients were *** Neoadjuvant use of FEC followed by T with concurrent celecoxib appeared to be safe for treatment of operable invasive breast *** observed lower incidence of chemotherapy-induced neutropenia is possibly contributed by the administration of *** believe that further investigation might provide more evidence on the use of COX-2 inhibitors in breast cancer.